MET and NF2 Alterations Confer Primary and Early Resistance to First-Line Alectinib Treatment in ALK-positive Non-Small-cell Lung Cancer.

Jie Hu,Ning Ding,Xiaobo Xu, Yedan Chen,Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao,Donghui Zhang, Yijun Song,Yang Shao,Yuanlin Song

Molecular oncology（2025）

Cited 0|Views2

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined